Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                HIV Treatment

HIV Treatment

                        HIV Treatment Information for Adults
          HIV Treatment Information for Children
          HIV Treatment Information for Pregnant Patients Home
          Drugs
          Drug Safety and Availability
          Information by Drug Class
          Human Immunodeficiency Virus (HIV)
          HIV Treatment
          HIV Treatment Information for AdultsHIV Treatment HIV Treatment Information for Adults
  
  					Get drug information for adult patients
	
    Share
    Post
    Linkedin

    Email
    PrintDosing is for adult patients ≥ 18 years unless noted otherwise

*Please refer to the most current drug label for adult patients with renal impairment

**General Considerations:**

Perform pregnancy testing before initiating an antiretroviral agent in adolescents and adults of childbearing potential




Filter by

Drug Class CD4-directed post-attachment HIV-1 inhibitorCombination ProductsCYP3A InhibitorEntry Inhibitors - CCR5 co-receptor antagonistFusion InhibitorsIntegrase InhibitorsNucleoside Reverse Transcriptase InhibitorsProtease Inhibitors

**Clear Filter | Search**





Recommended Adult Dosing of Antiretrovirals

	Adult dosages for the treatment of HIV-1 infection over 18 years of age.
	Brand
			Generic
			Drug Class
			Dosage Form
			Adult Dosing
			Visit Drugs@FDA to viewAtripla*
			efavirenz 600 mg
			emtricitabine 200 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			One tablet once daily on an empty stomach, preferably at bedtime
			Atripla LabelBiktarvy*
			bictegravir 50 mg
			emtricitabine 200 mg
			tenofovir alafenamide 25 mg
			Combination Products
			Oral Tablet
			One tablet once daily with or without food
			Biktarvy LabelCimduo*
			lamivudine 300 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			One tablet once daily with or without food
			Cimduo LabelCombivir*
			zidovudine 300 mg
			lamivudine 150 mg
			Combination Products
			Oral Tablet
			One tablet twice daily
			Combivir LabelComplera*
			emtricitabine 200 mg
			rilpivirine 25 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			One tablet once daily with food
			Complera LabelDelstrigo*
			doravirine 100 mg
			lamivudine 300 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			One tablet once daily with or without food
			Delstrigo LabelDescovy*
			emtricitabine 200 mg
			tenofovir alafenamide 25 mg
			Combination Products
			Oral Tablet
			One tablet once daily with or without food
			Descovy LabelDovato*
			dolutegravir 50 mg
			lamivudine 300 mg
			Combination Products
			Oral Tablet
			One tablet once daily with or without food
			Dovato LabelEpzicom*
			abacavir 600 mg
			lamivudine 300 mg
			Combination Products
			Oral Tablet
			One tablet once daily with or without food
			Epzicom LabelEvotaz*
			atazanavir 300 mg
			cobicistat 150 mg
			Combination Products
			Oral Tablet
			For treatment-naive and -experienced adults: One tablet once daily with food
			Evotaz LabelGenvoya*
			elvitegravir 150 mg
			cobicistat 150 mg
			tenofovir alafenamide 10 mg
			emtricitabine 200 mg
			Combination Products
			Oral Tablet
			One tablet once daily with food
			Genvoya LabelJuluca
			dolutegravir 50 mg
			rilpivirine 25 mg
			Combination Products
			Oral Tablet
			One tablet once daily with a meal
			Juluca LabelKaletra
			lopinavir 100 mg and ritanovir 25 mg
			lopinavir 200 mg and ritonavir 50 mg
			Combination Products
			Oral Tablet
			Given once daily or twice daily regimen with or without food. Please see Full Prescribing Information for dosing regimen.
			Kaletra LabelKaletra
			lopinavir 80 mg/mL and ritonavir 20 mg/mL
			Combination Products
			Oral Solution
			Given once daily or twice daily regimen with food. Please see Full Prescribing Information for dosing regimen.
			Kaletra LabelOdefsey*
			emtricitabine 200 mg
			rilpivirine 25 mg
			tenofovir alafenamide 25 mg
			Combination Products
			Oral Tablet
			One tablet once daily with a meal
			Odefsey LabelPrezcobix*
			darunavir 800 mg
			cobicistat 150 mg
			Combination Products
			Oral Tablet
			For treatment-naïve and treatment-experienced adults with no darunavir resistance associated substitutions: one tablet once daily with food
			Prezcobix LabelStribild*
			elvitegravir 150 mg
			cobicistat 150 mg
			emtricitabine 200 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			One tablet once daily with food
			Stribild LabelSymfi*
			efavirenz 600 mg
			lamivudine 300 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			One tablet once daily on an empty stomach, preferably at bedtime
			Symfi LabelSymfi Lo*
			efavirenz 400 mg
			lamivudine 300 mg
			tenofovir disoproxil fumarate 300 mg
			Combination Products
			Oral Tablet
			One tablet once daily on an empty stomach, preferably at bedtime
			Symfi Lo LabelSymtuza*
			darunavir 800 mg
			cobicistat 150 mg
			emtricitabine 200 mg
			tenofovir alafenamide 10 mg
			Combination Products
			Oral Tablet
			One tablet once daily with food
			Symtuza LabelTriumeq*
			dolutegravir 50 mg
			abacavir 600 mg
			lamivudine 300 mg
			Combination Products
			Oral Tablet
			One tablet once daily with or without food
			Triumeq LabelTrizivir*
			abacavir 300 mg
			lamivudine 150 mg
			zidovudine 300 mg
			Combination Products
			Oral Tablet
			One tablet twice daily with or without food
			Trizivir LabelTruvada*
			emtricitabine (FTC), tenofovir disoproxil fumarate (TDF):
			100 mg FTC/150 mg TDF
			133 mg FTC/200 mg TDF
			167 mt FTC/250 mg TDF
			200 FTC/300 mg TDF
			Combination Products
			Oral Tablet
			One tablet once daily with or without food
			Truvada LabelEmtriva*
			emtricitabine 200 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			One capsule once daily with or without food
			Emtriva LabelEmtriva*
			emtricitabine 10 mg/mL
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Solution
			240 mg (24 mL) once daily with or without food
			Emtriva LabelEpivir*
			lamivudine 150 mg, 300 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			150 mg tablet twice daily or 300 mg tablet once daily with or without food
			Epivir LabelEpivir*
			lamivudine 10 mg/mL
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Solution
			30 mL (300 mg) daily max with or without food
			Epivir LabelRetrovir*
			zidovudine 100 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			300 mg twice daily
			Retrovir LabelRetrovir*
			zidovudine 10 mg/mL
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Syrup
			30mL (300 mg) twice daily
			Retrovir LabelRetrovir*
			zidovudine 20-ml single-use vial (10 mg/mL)
			Nucleoside Reverse Transcriptase Inhibitors
			Intravenous Injection
			Recommended dose: 1 mg/kg infused at a constant rate over 1 hour every 4 hours
			Retrovir LabelTemixys*
			lamivudine 300 mg
			tenofovir disoproxil fumarate 300 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			One tablet once daily with or without food
			Temixys LabelVidex*
			didanosine 2 g, 4 g
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Powder for Solution
			Dosing is based on body weight and administered on an empty stomach at least 30 minutes before or 2 hours after eating. Please see Full Prescribing Information for dosing.
			Videx LabelVidex EC*
			didanosine delayed-release capsule 125 mg, 200 mg, 250 mg, 400 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			Dosing is based on body weight and administered on an empty stomach once daily. Please see Full Prescribing Information for details
			Videx EC LabelViread*
			tenofovir disoproxil fumarate 150 mg, 200 mg, 250 mg, 300 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			• For patients weighing at least 35 kg, one tablet (300 mg) taken orally once daily without regard to food
			• For patients weighing at least 17 kg who can swallow an intact tablet, one tablet (150 mg, 200 mg, 250 mg, or 300 mg based on body weight) once daily taken orally without regard to food. Please see Full Prescribing Information for details
			Viread LabelViread*
			tenofovir disoproxil fumarate 40 mg per gram of powder
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Powder
			8 mg per kg oral powder (up to a maximum of 300 mg) taken once daily with soft food
			Viread LabelZerit*
			stavudine 15 mg, 20 mg, 30 mg, 40 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			•For patients weighing less than 60 kg: 30 mg every 12 hours
			•For patients weighing at least 60 kg: 40 mg every 12 hours
			Zerit LabelZiagen
			abacavir 300 mg
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			• Administered as either 300 mg twice daily or 600 mg once daily
			Ziagen LabelZiagen
			abacavir 20 mg/mL
			Nucleoside Reverse Transcriptase Inhibitors
			Oral Solution
			• Administered as either 15 mL (300 mg) twice daily or 30 mL (600 mg) once daily
			• For patients with mild hepatic impairment (Child-Pugh A): 10 mL twice daily. Ziagen is contraindicated in patients with moderate to severe hepatic impairment
			Ziagen LabelEdurant
			rilpivirine 25 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			One tablet once daily with a meal
			Edurant LabelIntelence
			etravirine 25 mg, 100 mg, 200 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			200 mg (one 200-mg tablet or two 100-mg tablet) twice daily following a meal
			Intelence LabelPifeltro
			doravirine 100 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			One tablet once daily with or without food
			Pifeltro LabelRescriptor
			delavirdine 200 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			400 mg (four 100-mg tablets, or two 200-mg tablets as intact tablets) three times daily for patients with or without food
			Rescriptor LabelSustiva
			efavirenz 600 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			600 mg once daily on an empty stomach, preferably at bedtime. Please see the Full Prescribing Information for dosage adjustment if taken with other medications.
			Sustiva LabelSustiva
			efavirenz 50 mg, 200 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Capsule
			600 mg once daily on an empty stomach, preferably at bedtime. Please see the Full Prescribing Information for dosage adjustment if taken with other medications.
			Sustiva LabelViramune*
			nevirapine 200 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			200 mg once daily for 14 days followed by 200 mg twice daily
			Viramune LabelViramune*
			nevirapine 50 mg/5 mL
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Suspension
			20 mL once daily for 14 days followed by 20 mL twice daily
			Viramune LabelViramune XR*
			nevirapine extended-release 400 mg
			Nonnucleoside Reverse Transcriptase Inhibitors
			Oral Tablet
			Must initiate therapy with one 200 mg tablet of immediate-release VIRAMUME once daily for the first 14 days, followed by one 400 mg tablet of VIRAMUNE XR daily.
			Patients already on the immediate-release VIRAMUNE twice daily can be switched to VIRAMUNE XR 400 mg once daily without the 14-day lead-in period of immediate-release VIRAMUNE. Please see Full Prescribing Information for dosing details
			Viramune XR LabelAptivus
			tipranavir 250 mg
			Protease Inhibitors
			Oral Capsule
			500 mg (two 250 mg capsules) co-administered with 200 mg of ritonavir, twice daily can be taken with or without meals
			Aptivus LabelAptivus
			tipranavir 100 mg/mL
			Protease Inhibitors
			Oral Solution
			5 mL oral solution co-administered with 200 mg of ritonavir, twice daily can be taken with or without meals
			Aptivus LabelCrixivan
			indinavir 200 mg, 400 mg
			Protease Inhibitors
			Oral Capsule
			800 mg (usually two 400-mg capsules) every 8 hours without food but with water 1 hour before or 2 hours after a meal
			Crixivan LabelInvirase
			saquinavir mesylate 500 mg
			Protease Inhibitors
			Oral Tablet
			• 1000 mg in combination with ritonavir 100 mg twice daily
			• Treatment-naïve patients initiating treatment with INVIRASE/ritonavir: First 7 days of treatment: INVIRASE 500 mg twice daily with ritonavir 100 mg twice daily. After 7 days: INVIRASE 1,000 mg twice daily with ritonavir 100 mg twice daily.
			•Please see Full Prescribing Information for dosing details for those switching from another regimen
			Invirase LabelLexiva
			fosamprenavir 700 mg
			Protease Inhibitors
			Oral Tablet
			Dosing based on combination with ritonavir. Take tablets with or without food. Please see Full Pescribing Information for dosing details.
			Lexiva LabelLexiva
			fosamprenavir 50 mg/mL
			Protease Inhibitors
			Oral Suspension
			Dosing based on combination with ritonavir. Take oral suspension without food. Please see Full Pescribing Information for dosing details.
			Lexiva LabelNorvir
			ritonavir 100 mg
			Protease Inhibitors
			Oral Tablet
			600 mg twice daily to be taken with meals
			Norvir LabelNorvir
			ritonavir 100 mg/packet
			Protease Inhibitors
			Oral Powder
			600 mg twice daily to be taken with meals
			Norvir LabelNorvir
			ritonavir 80 mg/mL
			Protease Inhibitors
			Oral Solution
			7.5 mL (600 mg) twice daily to be taken with meals
			Norvir LabelPrezista
			darunavir 75 mg, 150 mg, 600 mg, 800 mg
			Protease Inhibitors
			Oral Tablet
			• Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (one 800 mg tablet) taken with ritonavir 100 mg (one 100 mg tablet or capsule or 1.25 mL of a 80 mg per mL ritonavir oral solution) once daily and with food.
			• Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg (one 100 mg tablet or capsule or 1.25 mL of a 80 mg per mL ritonavir oral solution) twice daily and with food. Please see Full Prescribing Information for dosing with oral solution.
			Prezista LabelPrezista
			darunavir 100 mg/mL
			Protease Inhibitors
			Oral Suspension
			• Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 8 mL (one 800 mg tablet) taken with ritonavir 100 mg ( 1.25 mL of a 80 mg per mL ritonavir oral solution) once daily and with food.
			• Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 6 mL (one 600 mg tablet) taken with ritonavir 100 mg (1.25 mL of a 80 mg per mL ritonavir oral solution) twice daily and with food. Please see Full Prescribing Information for dosing with oral solution.
			Prezista LabelReyataz*
			atazanavir sulfate 150 mg, 200 mg, 300 mg
			Protease Inhibitors
			Oral Capsule
			• Treatment-naive adults: 300 mg with ritonavir 100 mg once daily with food or 400 mg once daily with food.
			• Treatment-experienced adults: 300 mg with ritonavir 100 mg once daily with food.
			Please see Full Prescribing Information for dosing details for dosing with other antiretoriviral drugs and H2-receptor antagonists.
			Reyataz LabelReyataz*
			atazanavir sulfate 50 mg/packet
			Protease Inhibitors
			Oral Powder
			• Treatment-naive adults: 300 mg with ritonavir 100 mg once daily with food or 400 mg once daily with food.
			•Treatment-experienced adults: 300 mg with ritonavir 100 mg once daily with food. REYATAZ oral powder must be mixed with food or beverage for administration and ritonavir must be given immediately afterwards.
			Please see Full Prescribing Information for dosing details for dosing with other antiretoriviral drugs and H2-receptor antagonists.
			Reyataz Label InformationViracept
			nelfinavir mesylate 250 mg, 625 mg
			Protease Inhibitors
			Oral Tablet
			1250 mg (five 250 mg tablets or two 625 mg tablets) twice daily or 750 mg (three 250 mg tablets) three times daily with a meal
			Viracept LabelFuzeon
			enfuvirtide lyophilized powder 108 mg/vial
			Fusion Inhibitors
			Subcutaneous Injection
			90 mg (1 mL) twice daily injected subcutaneously into the upper arm, anterior thigh or abdomen
			Fuzeon LabelSelzentry*
			maraviroc 25 mg, 75 mg, 150 mg, 300 mg
			Entry Inhibitors - CCR5 co-receptor antagonist
			Oral Tablet
			Dosing based on concomitant medications taken twice with or without food. Please see Full Prescribing for dosing recommendations.
			Selzentry LabelSelzentry*
			maraviroc 20 mg/mL
			Entry Inhibitors - CCR5 co-receptor antagonist
			Oral Solution
			Dosing based on concomitant medications taken twice with or without food. Please see Full Prescribing for dosing recommendations.
			Selzentry LabelIsentress
			raltegravir film-coated 400 mg
			Integrase Inhibitors
			Oral Tablet
			• Treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily: 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or 400 mg film-coated tablet orally, twice daily.
			• Treatment experienced patients: 400 mg film-coated tablet orally, twice daily.
			• During coadministration with rifampin in adults, 800 mg (2 x 400 mg) twice daily.
			*Do not substitute ISENTRESS chewable tablets or ISENTRESS for oral suspension for the ISENTRESS 400 mg film-coated tablet or the ISENTRESS HD 600 mg film-coated tablet as the formulations have different pharmacokinetic profiles.
			Isentress LabelIsentress HD
			raltegravir HD film-coated 600 mg
			Integrase Inhibitors
			Oral Tablet
			• Treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily: 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or 400 mg film-coated tablet orally, twice daily.
			• Treatment experienced patients: 400 mg film-coated tablet orally, twice daily.
			• During coadministration with rifampin in adults, 800 mg (2 x 400 mg) twice daily.
			*Do not substitute ISENTRESS chewable tablets or ISENTRESS for oral suspension for the ISENTRESS 400 mg film-coated tablet or the ISENTRESS HD 600 mg film-coated tablet as the formulations have different pharmacokinetic profiles.
			Isentress Label InformationIsentress
			raltegravir 25 mg, 100 mg
			Integrase Inhibitors
			Oral Chewable Tablet
			May be chewed or swallowed whole. Maximum daily dose is 300 mg taken by mouth twice daily
			Isentress LabelIsentress
			raltegravir 100 mg/packet
			Integrase Inhibitors
			Oral Suspension
			Maximum daily dose is 100 mg taken by mouth twice daily
			Isentress LabelTivicay*
			dolutegravir 10 mg, 25 mg, 50 mg
			Integrase Inhibitors
			Oral Tablet
			50 mg once to two times daily depending on treatment experience with or without food. Please see Full Prescribing Information for dosing details.
			Tivicay LabelTrogarzo
			ibalizumab-uiyk 150mg/ml
			CD4-directed post-attachment HIV-1 inhibitor
			Intravenous Injection
			Administered intravenously (IV) as a single loading dose of 2,000 mg (10 vials) followed by a maintenance dose of 800 mg (4 vials) every 2 weeks after dilution in 250 mL of 0.9% Sodium Chloride Injection, USP
			Trogarzo LabelTybost*
			cobicistat 150 mg
			CYP3A Inhibitor
			Oral Tablet
			Must be in combination with atazanavir or darunavir at the same time, with food, and in combination with other HIV-1 antiretroviral agents.
			• 150 mg orally once daily with atazanavir 300 mg orally once daily for treatment-naive or treatment-experienced.
			• 150 mg orally once daily with darunavir 800 mg orally once daily in treatment-naive or treatment-experienced patients with no darunavir resistance-associated substitutions.
			Please see Full Prescribing Information for dosing details.
			Tybost Label



Learn about approved and tentatively approved antiretrovirals eligible for procurement under the President's Emergency Plan for AIDS Relief (PEPFAR)”

                                                                                  Content current as of:
      08/07/2020
              
              
Regulated Product(s)
		 Drugs
			  			     			  						              
			
			
			
			
						  HIV/AIDS Drugs
			  			     			  			     Generic DrugsHealth Topic(s)
			  Sexually Transmitted Diseases (STDs)
			    			       			    			       HIV/AIDSLaw(s) & Regulation(s)
			  President's Emergency Plan for AIDS Relief (PEPFAR)HIV Treatment

          
                        HIV Treatment Information for Adults
          HIV Treatment Information for Children
          HIV Treatment Information for Pregnant Patients
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop